Insights from Personify Health's Chief Medical Officer

With obesity rates and healthcare costs continuing to rise, GLP-1 medications like Ozempic and Wegovy have captured employers' attention, promising significant weight loss and healthcare savings.

Leading many organizations to question and evaluate whether GLP-1s are a worthwhile investment for their populaiton.

It is critical that employers, health plans, and providers provide people with a solution that includes support for behavior change and mental health needs — either complementary to the drug or instead of it.

Download this guide with insights from our Chief Medical Officer to explore:

✅ The true driver behind escalating healthcare costs: obesity
✅ A history of GLP-1s and how they work
✅ Answers to the question - "Should I cover GLP-1s for my employees who want to lose weight?" with insights from +60 client consultation this year

✅ A 5-step plan for a holistic, sustainable approach to weight management